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Abstract: The prognostic value of Toll-like receptor 3 (TLR3) is debated in cancer, differing between
tumor types, methods, and cell types. We recently showed for the first time that TLR3 expression on
early stage non-small-cell lung cancer (NSCLC) results associated with a good prognosis. Here, we
provide experimental evidences explaining the molecular reason behind TLR3’s favorable prognostic
role. We demonstrated that TLR3 activation in vitro induces apoptosis in lung cancer cell lines and,
accordingly, that TLR3 expression is associated with caspase-3 activation in adenocarcinoma NSCLC
specimens, both evaluated by immunohistochemistry. Moreover, we showed that TLR3 expression
on cancer cells contributes to activate the CD103+ lung dendritic cell subset, that is specifically
associated with processing of antigens derived from apoptotic cells and their presentation to CD8+ T
lymphocytes. These findings point to the relevant role of TLR3 expression on lung cancer cells and
support the use of TLR3 agonists in NSCLC patients to re-activate local innate immune response.
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1. Introduction
To date, major efforts have focused on therapeutic strategies to overcome cancer resistance to
immunosurveillance. A successful approach is based on the administration of TLRs ligands to boost
antitumor immunity. Toll-like receptors (TLRs) are expressed primarily on immune cells, where
they activate downstream signaling cascades that induce the secretion of cytokines and chemokines,
culminating in innate and adaptive immune responses against pathogens [1]. Activation of TLRs on
professional antigen-presenting cells, such as dendritic cells (DCs), is also crucial for their maturation,
their homing into lymph nodes, and to start cytokines production that is necessary for the activation of
T-cells [2]. Particularly, various TLR3 agonists are being used in cancer treatments, [3–5] and interest
in these TLR3 agonists in clinical use as adjuvant for the activation of immune system is constantly
growing [6–8].
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TLR3, like other TLRs, is also expressed on epithelial cells, including cancer cells of several
histotypes [9]. Similar to immune cells, cancer cells respond to TLR3 ligands by secreting inflammatory
cytokines, type I interferon (IFN I), and chemokines, which enhance the recruitment and activation of
immune cells. In addition, TLR3 activation has been reported to mediate apoptosis in several cancer
histotypes, primarily through an extrinsic pathway [10]. This unusual function of tumoral TLR3 has
increased clinical interest in its targeting, prompting efforts to exploit the direct apoptotic effects of
TLR3 on cancer cells [3]. Evidences on hepatocellular carcinoma (HCC), neuroblastomas or esophageal
squamous cell carcinoma showed that TLR3 expression by the tumor parenchyma has been associated
with a favorable prognosis (reviewed in [11,12]), and we recently observed that in early NSCLC, TLR3
expression on cancer cells is also significantly associated with good overall survival [13].
Our evidence of the prognostic role of TLR3 expression on lung cancer cells reveals the possibility
to exploit TLR3 activation to induce cancer cells apoptosis, concurrently with immune activation.
Moreover, the induction of apoptosis in lung cancer cells and the release of apoptotic bodies could also
contribute to boosting the immune system through immunogenic cell death [14].
Here, we observed that activation of TLR3 causes apoptosis in lung tumor cells in vitro.
To determine the relevance of TLR3-induced apoptosis in lung cancer cells in driving good prognosis in
NSCLC patients, we explored the expression of cleaved caspase-3 in NSCLC specimens, highlighting
that TLR3 expression correlates with cleaved caspase-3 expression in lung adenocarcinoma. Moreover,
lung cancer cell death contributed to the activation of CD103+ lung dendritic cells. Collectively, our
data indicate that all these TLR3-mediated mechanisms could contribute to explain the association
between TLR3 expression on NSCLC tumor cells and a favorable prognosis.
2. Results
2.1. TLR3 Induces Apoptosis in Lung Tumor Cells
Two human lung cancer cell lines that express TLR3 (Figure S1)—Calu-3 (adenocarcinoma) and
H460 (large cell carcinoma)—were treated with a synthetic TLR3 agonist, Poly(I:C), to mimic the
effects of viral dsRNAs in vitro. Poly(I:C) was combined with IFN type I that is reportedly necessary
but not sufficient to activate the apoptotic pathway in melanoma and breast cancer cells [15,16].
Cytofluorimetric annexin V assay showed that around 30% of Calu-3 and of H460 cells die after 48 h
incubation with 100 µg/mL Poly(I:C), in combination with 100 U/mL INFα (Figure 1A–D). TUNEL
assay confirmed apoptosis in 20% and 40% of Poly(I:C)/INFα-treated Calu-3 and H460 cancer cells,
respectively, compared with untreated control cells (Figure 1E,F).
TLR3-mediated mechanism of apoptosis in cancer cells is dependent on caspase-8 activation [10,17],
which activates caspase-3 by proteolytic cleavage to amplify caspase-8 apoptosis initiation signals [18].
Consistently, an increase in caspase-3 cleavage was observed in Poly(I:C)/INFα-treated cancer cells
(Figure S2).
In Calu-3 and H460 cells, the specific TLR3 agonist Poly(A:U), combined with INFα, induced a
30% increase in the apoptotic cell fraction vs. untreated cells (Figure S3). Since Poly(A:U) is unable to
activate MDA5/RIG1, a cytosolic dsRNA recognition receptor alternative to TLR3 that can be bound by
Poly(I:C), this data suggests that apoptosis that occurred following treatment with Poly(I:C)/INFα in
Calu-3 and H460 cells was related to the specific activation of TLR3.
2.2. TLR3 Expression on Cancer Cells Associated with Higher Apoptosis in NSCLC Adenocarcinoma
We examined whether induction of apoptosis in vitro observed upon activation of TLR3 in lung
cancer cells also occurs in NSCLC patients with TLR3 expressing tumor. TLR3 protein expression
was analyzed in 45 human primary NSCLC specimens that were collected at ASST Grande Ospedale
Metropolitano Niguarda. Median age was 65.5 years, 67% were male and 76% were adenocarcinoma
(Table S1).
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Figure 1. TLR3 activation by Poly(I:C) induces apoptosis in lung cancer cell lines. To determine the 
percentage of apoptotic cells on TLR3 activation in lung cancer cells, Calu3 (A,C) and H460 (B,D) 
cells were left untreated (NT) or treated with Poly (I:C), IFNα, or their combination for 48 h. 
Harvested cells were processed by annexin V apoptosis assay. To evaluate the apoptotic cells 
fractions (expressed as percentage of total number of cells evaluated) of each sample, we considered 
cells in early and late apoptosis phases, then combining the percentage of cells positive for Annexin 
V, regardless of TO-PRO-3 staining. Approximately 30% of cells were apoptotic on TLR3 activation 
in both lung cancer cell lines. The experiment shown in panels A and B is representative of four 
independent experiments. To calculate the percentage of apoptotic cells ratios, the obtained 
percentages of total apoptotic cells treated with Poly(I:C)+IFNα were divided for the percentage of 
total apoptotic cells of the untreated samples, set as reference. The apoptotic ratio increase was 
confirmed by TUNEL assay (E,F). * p value < 0,05, ** p value < 0.005, *** p value < 0.001.  
Figure 1. TLR3 activation by Poly(I:C) induces apoptosis in lung cancer cell lines. To determine the
percentage of apoptotic cells on TLR3 activation in lung cancer cells, Calu3 (A,C) and H460 (B,D) cells
were left untreated (NT) or treated with Poly (I:C), IFNα, or their combination for 48 h. Harvested
cells were processed by annexin V apoptosis assay. To evaluate the apoptotic cells fractions (expressed
as percentage of total number of cells evaluated) of each sample, we considered cells in early and
late apoptosis phases, then combining the percentage of cells positive for Annexin V, regardless of
TO-PRO-3 staining. Approximately 30% of cells were apoptotic on TLR3 activation in both lung
cancer cell lines. The experiment shown in panels A and B is representative of four independent
experiments. To calculate the percentage of apoptotic cells ratios, the obtained percentages of total
apoptotic cells treated with Poly(I:C)+IFNα were divided for the percentage of total apoptotic cells of
the untreated samples, set as reference. The apoptotic ratio increase was confirmed by TUNEL assay
(E,F). * p value < 0,05, ** p value < 0.005, *** p value < 0.001.
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IHC performed on FFPE NSCLC specimens showed TLR3 and caspase-3 expression in tumor
cells (Figure 2A). TLR3 and caspase-3 expression were scored as described in Materials and Methods
section. Considering all cases, no correlation emerged between TLR3 and caspase-3 expression in
tumor cells; whereas, by considering only lung adenocarcinoma, a significant direct correlation was
observed (Figure 2B; p = 0.0340, Pearson test; n = 33). Indeed, cases with an elevated percentage of
tumor cells expressing caspase-3 showed concurrently a high percentage of tumor cells expressing
TLR3 (>50% of total tumor cells; score 2, 3, 4); conversely, most of the cases (11/13 cases, 85%) with
TLR3 low expression on tumor cells showed a concomitant low expression of caspase-3 on tumor cells
(≤25% of total tumor cells; score 0, 1).
Int. J. Mol. Sci. 2020, 21, 1440 4 of 15 
 
TLR3-mediated mechanism of apoptosis in cancer cells is dependent on caspase-8 activation 
[10, 17], which activates caspase-3 by proteolytic cleavage to amplify caspase-8 apoptosis initiation 
signals [18]. Consistently, an increase in caspase-3 cleavage was observed in Poly(I:C)/INFα-treated 
cancer cells (Figure S2). 
In Calu-3 and H460 cells, the specific TLR3 agonist Poly(A:U), combined with INFα, induced a 
30% increase in the apoptotic cell fraction vs. untreated cells (Figure S3). Since Poly(A:U) is unable to 
activate MDA5/RIG1, a cytosolic dsRNA recognition receptor alternative to TLR3 that can be bound 
by Poly(I:C), this data suggests that apoptosis that occurred following treatment with 
Poly(I:C)/INFα in Calu-3 and H460 cells was related to the specific activation of TLR3. 
2.2. TLR3 Expression on Cancer Cells Associated with Higher Apoptosis in NSCLC Adenocarcinoma 
We examined whether induction of apoptosis in vitro observed upon activation of TLR3 in lung 
cancer cells also occurs in NSCLC patients with TLR3 expressing tumor. TLR3 protein expression 
was analyzed in 45 human primary NSCLC specimens that were collected at ASST Grande Ospedale 
Metropolitano Niguarda. Median age was 65.5 years, 67% were male and 76% were adenocarcinoma 
(Table S1). 
IHC performed on FFPE NSCLC specimens showed TLR3 and caspase-3 expression in tumor 
cells (Figure 2A). TLR3 and caspase-3 expression were scored as described in Materials and Methods 
section. Considering all cases, no correlation emerged between TLR3 and caspase-3 expression in 
tumor cells; whereas, by considering only lung adenocarcinoma, a significant direct correlation was 
observed (Figure 2B; p = 0.0340, Pearson test; n = 33). Indeed, cases with an elevated percentage of 
tumor cells expressing caspase-3 showed concurrently a high percentage of tumor cells expressing 
TLR3 (>50% of total tumor cells; score 2, 3, 4); conversely, most of the cases (11/13 cases, 85%) with 
TLR3 low expression on tumor cells showed a concomitant low expression of caspase-3 on tumor 
cells (≤25% of total tumor cells; score 0, 1). 
 
Figure 2. TLR3 and caspase-3 immunohistochemical expression in NSCLC. TLR3 and caspase-3 
immunohistochemical staining were performed on FFPE NSCLC sections as described in Materials 
and Methods. TLR3 and caspase-3 expression was defined as the percentage of positive cells of the 
total number of cancer cells in the sample in tumor (IHC score: 0= no positive cells; 1 ≤ 25%; 25% < 2 ≤ 
50%; 50% < 3 ≤75%; 4 > 75%). (A) Images of cases positive and negative both for TLR3 and caspase-3 
in the tumor cells. Images are acquired at 20× magnification. (B) Correlation analysis between 
percentage of IHC-positive cells for TLR3 expression with percentage of IHC-positive cells for 
caspase-3 expression in the tumor in adenocarcinoma NSCLC (n = 33; p = 0,0365; Pearson r = 0,3655; 
95% confidence interval 0.02532 to 0.6299). Shape size is related to the number of cases represented. 
Figure 2. TLR3 and caspase-3 immunohistochemical expression in NSCLC. TLR3 and caspase-3
immunohistochemical staining were performed on FFPE NSCLC sections as described in Materials and
Methods. TLR3 and caspase-3 expression was defined as the percentage of positive cells of the total
number of cancer cells in the sample in tumor (IHC score: 0= no positive cells; 1 ≤ 25%; 25% < 2 ≤ 50%;
50% < 3 ≤75%; 4 > 75%). (A) Images of cases positive and negative both for TLR3 and caspase-3 in the
tumor cells. Images are acquired at 20×magnification. (B) Correlation analysis between percentage of
IHC-positive cells for TLR3 expression with percentage of IHC-positive cells for caspase-3 expression
in the tumor in adenocarcinoma NSCLC (n = 33; p = 0,0365; Pearson r = 0,3655; 95% confidence interval
0.02532 to 0.6299). Shape size is related to the number of cases represented.
We previously analyzed a cohort of 194 human primary NSCLC specimens (who had been
diagnosed between 2003 and 2007 at our institute Fondazione IRCCS Istituto Nazionale Tumori
Milan, selected all stage I, with a median follow-up time of 105.7 months) [13], showing a significant
association between prognosis (Overall Survival, OS) and TLR3 tumor expression. Here, a new
association analysis between OS and TLR3 immunohistochemistry expression on tumor cells has
been explored according with NSCLC histology. TLR3 expression was significantly associated with
prognosis strongly in subjects with adenocarcinoma (p = 0.0117; HR = 0.389, Cl = 0.187–0.811; n = 117)
(Figure 3A), whereas no significant association between TLR3 expression on tumor cells and prognosis
was observed considering only squamous carcinoma (p = 0.8826; HR = 1.056, Cl = 0.512–2.176; n = 52)
(Figure 3B).
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Moreover, a correlation between TLR3 and caspase-3 mRNA expression in adenocarcinoma 
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Moreover, by in silico analysis of NSCLC patients in the KM-Plotter public NSCLC gene expression
dataset [19] according with TLR3 expression, the histotype of NSCLC resulted in being an important
determinant for the association between TLR3 and good prognosis. Indeed, TLR3 expression was
significantly associated with a good prognosis in adenocarcinoma (Figure 4A; p < 0.001; HR = 0.58;
n = 720) but not in squamous carcinoma (Figure 4B; p = 0.91; HR = 1.01; n = 524). According with
tumor stage, we observed that both in stage I and stage II adenocarcinoma, TLR3 was significantly
associated with a good prognosis (Figure 4C; p = 0.0032; HR = 0.5; n = 370) (Figure 4D; p = 0.021;
HR = 0.52; n = 136). In agreement, a significantly higher time to first progression (FP) was observed in
NLSLC patients expressing TLR3 mRNA, highlighting the association between TLR3 expression and
recurrence (Supplementary Figure S4).
Moreover, a correlation between TLR3 and caspase-3 mRNA expression in adenocarcinoma
patients was investigated through the ultiple gene analysis options of the KM-Plotter public NSCLC
gene expression dataset. A light correlation between TLR3 and caspase-3 mRNA expression was
observed in adenocarcinoma patients (all cases, Spearman coefficient 0.5682; only stage I, S earman
coefficient 0.6415).
These data support the role of TLR3 expression in inducing apoptosis i lung adenocarcinoma cells.
2.3. TLR3 Boosts the Innate Immune Response
We explore the possibility that TLR3-mediated apoptosis activates immune cells against the tumor.
Of the various populations of lung dendritic cells (DCs), the CD103+ subset is specifically deputed in
the lung to process antigens from apoptotic cells and to present them to CD8+ T lymphocytes, inducing
the activation of adaptive immune cells [20]. Thus, we determined whether the induction of apoptosis
in lung tumor cells by TLR3 agonist treatment specifically activates the CD103+ cell subpopulation.
An in vitro co-culture of lung-infiltrating immune cells, derived from immunocompetent mice and
TLR3-positive tumor cells that were pretreated with Poly(I:C)/INFα, was established (Figure S3 and
Figure S4 describe the experimental flowchart and gating strategy, respectively). Expression of cell
surface markers CD80, CD86 and CD83 have been assessed to evaluate the percentage of activated
immune cells.
The total number of activated CD103+ CD86+ and of CD103+ CD80+ cell subsets rose 10%
and 12% by FACS, respectively, in the immune cells co-cultured with Poly(I:C)/INFα-treated-H460
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cancer cells versus untreated H460 cells (Figure 5A). CD103+ CD83+ cells increased by 4% (Figure 5A).
A similar increase in the CD103+ fractions, which were positive for CD80, CD83 and CD86 activation
markers, was observed in Calu-3 cells (Figure S7). Higher expression of these markers, albeit to a lesser
extent, was also observed in conventional dendritic cells (CD11b+ CD11c+ CD103− DCs) (Figure 5B)
(+4% CD86 and +3% CD80), but CD86, CD83, and CD80 were not upregulated in alveolar macrophages
(Figure 5C).Int. J. Mol. Sci. 2020, 21, 1440 6 of 15 
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The relationship between TLR3 expression and prognosis was examined in the KM-Plotter public
gene expression NSCLC datasets [19]. NSCLC patients were strat fied by tertiles with regard to
TLR3 mRNA expression (probe ID 206271_at). Red li e: high TLR3 expression; black line: low TLR3
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I adenocarcinoma NSCLC cases, n = 370. (D) Overall survival probability of patients by TLR3 mRNA
levels in only stage II adenocarcinoma NSCLC cases, n = 136.
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These findings indicate that the in vitro stimulation of TLR3-positive human lung cancer cells
with synthetic TLR3 agonist induces apoptosis in tumor cells and that TLR3-mediated apoptosis of
lung cancer cells increases the activation of the CD103+ subset of lung dendritic cells.
3. Discussion
We and others observed the expression of TLR3 protein NSCLC specimens by
immunohistochemistry [13,21], and we revealed that the expression of TLR3 on tumor cells has
a favorable prognostic value in early stage human NSCLC [13]. Here, our evidences indicate the
promotion of apoptosis cascade and the engagement of the immune system as the two main outcomes of
TLR3 activation on tumor cells. The presence of exogenous or endogenous ligands, inhaled or released
from dying tumor cells, might sustain TLR3 activation, thus explaining the improved prognosis of
NSCLC patients with high TLR3 expression in tumor cells. In agreement with this hypothesis, in this
study we observed that specific stimulation of TLR3 with synthetic TLR3 agonists and INFα is able to
induce cell apoptotic program, culminating in the activation of caspase-3 in two human lung cancer
cell lines expressing TLR3. Furthermore, we also observed for the first time that TLR3 expression
on cancer cells is significantly associated with cleaved caspase-3 expression in a cohort of 45 human
primary adenocarcinoma NSCLC. The association between TLR3 and caspase-3 expression, as a proof
of the activation of apoptosis cascade in lung cancer, is supported by evidences in other cellular models
of different cancer types, including breast, melanoma, head and neck, prostate, renal carcinoma, colon,
and cervical cancers [10,11].
Here, we then showed that TLR3-mediated apoptosis of lung cancer cells indirectly contributes
to the activation of immune response against tumors. We showed that apoptotic bodies from dying
tumor cells stimulate APCs, rendering them more efficient with regard to antigen presentation [22].
In Calu-3 and H460 cells, TLR3-induced apoptosis primarily activates lung CD103+ DCs, a subset
of pulmonary DCs that preferentially acquires and presents apoptotic cell-associated antigens [20].
The capability of TLR3 agonists to boost the immune response in tumor microenvironment has been
widely investigated in preclinical models [23]. TLR3 stimulation triggers DC maturation through
expression of co-stimulatory molecules, leading to NK cells activation and promotion of cross-priming
that result in the CTLs induction [24,25]. Moreover, Poly(I:C) can in vivo convert lung tumor-associated
macrophages (TAM) from tumor supporters (M2) to those with tumoricidal properties (M1) [26]. Thus,
besides these effects of TLR3 activation on immune cells, our data indicate that TLR3 activation on
cancer cells by promoting apoptosis may in turn favor the activation of an immune response against
the tumor and thus improve the prognosis of lung cancer patients.
Considering all cases of NSCLC collected at Niguarda Hospital, no correlation emerged between
TLR3 and caspase-3 expression in tumor cells, whereas, by considering only lung adenocarcinomas,
a significant direct correlation was observed. Accordingly, when we analyzed the human primary
NSCLC specimens collected at Fondazione IRCCS Istituto Nazionale dei Tumori of Milan, which we
recently investigated for TLR3 expression [13], a benefit from TLR3 tumor expression was observed
only in subjects with adenocarcinoma, but not in patients with squamous carcinoma. We can speculate
that the antitumor effect of TLR3 activation on tumor cells depends on the histological characteristics
of the NSCLCs and the environmental immune context in which these tumors develop. In agreement,
Jiang et al. [27], based on the analysis of a set of immunological markers, reported that squamous
NSCLC is characterized by divergent clinical and molecular immune phenotypes compared with
non-squamous NSCLC. As a support of the relevance of NSCLC histotype to consider the TLR3
prognostic role, the in silico analysis of KM-Plotter database showed a better outcome in TLR3
expressing adenocarcinoma and no association between TLR3 expression and prognosis in squamous
NSCLC, both considering stage I and stage II NSCLC patients. A deeper characterization of the
complex and bidirectional cross-talk between TLR3-expressing cancer cells and immune populations is
thus required to define TLR3 feasibility both as a prognostic marker and therapeutic target.
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The method of TLRs’ agonists delivery still remains the major limitation to their clinical use,
since they exploit a major action when locally dosed, accordingly to the importance of innate effector
cell activation at the site of tumor growth [28]. A strategy we are currently evaluating to improve
the efficacy of TLRs agonists is the local administration. Indeed, we recently demonstrated that
aerosol administration of TLR3 agonist poly(I:C) in mouse models impaired lung metastatization
through activation of TLRs on lung cancer infiltrating immune cells [29]. Particularly, aerosolization
of CpG-ODN with Poly(I:C) into the bronchoalveolar space reduced the presence of M2-associated
arginase- and IL-10-secreting macrophages in tumor-bearing lungs and increased the antitumor activity
of aerosolized CpG-ODN alone against B16 lung metastases. This effect was due to an enhanced
recruitment and cytotoxic activity of tumor-infiltrating NK cells in the lung mediated by alveolar
macrophages [30].
Therefore, local administration of TLR3 agonists in NSCLC patients could lead to the re-activation
of local innate immune response and apoptosis of lung adenocarcinoma cells.
4. Materials and Methods
4.1. Cell Lines and Treatments
The human lung cancer cell lines Calu-3 and H460 were maintained at 37 ◦C in a humidified
atmosphere of 5% CO2 in air in RPMI 1640 (Life Technologies) supplemented with 10% fetal bovine
serum (FBS) and 2 mM glutamine (both from Life Technologies). For indicated treatment, the Calu-3
and H460 human lung cancer cell lines were seeded in 6-well plates and treated with 100 U/mL INFα,
as it is standard for determining the in vitro effects of TLR3 agonists [15]. After 24 h, the culture
medium was replaced with 100 µg/mL Poly (I:C) (LMW) (tlrl-picw, InvivoGen), or Poly(A:U) 500 µg/mL
(tlrl-pau, InvivoGen) and 100 U/mL INFα for additional 48 h.
4.2. Quantitative PCR Analysis
RNA was isolated using QIAzol (QIAGEN), according to the manufacturer’s instructions from lung
cancer cells. Reverse transcription was performed as we already described [31] using a High-Capacity
RNA-tocDNA Kit (Applied Biosystems-Thermo Fisher Scientific). Real-time PCR was performed
using TaqMan® Fast Universal PCR Master Mix (Applied Biosystems-Thermo Fisher Scientific) and
SDS 2.4 on a 7900HT Fast Real-Time PCR System (Applied Biosystems-Thermo Fisher Scientific).
The TaqMan® gene expression assays for TLR3 used was Hs01551078_m1 (Applied Biosystems-Thermo
Fisher Scientific). The expression of TLR3 gene was normalized to β2m (assay ID: Mm00437762_m1).
PCR data were analyzed using the 2−∆Ct method.
4.3. Cytofluorimetric Analysis of Lung Cancer Cell Apoptosis
The Calu-3 and H460 human lung cancer cell lines were left untreated or treated with 100 U/mL
INFα and after 24 h, the culture medium was replaced or not with 100 µg/mL Poly (I:C) (LMW)
(tlrl-picw, InvivoGen) for an additional 48 h. At the end of treatment, the supernatants from tumor cells,
containing debris, necrotic cells, and trypsin-detached cells, were centrifuged for 5 min at 1500 rpm.
The recovered cells were washed in 1× PBS. Cytofluorimetric analyses were performed with the Flow
Cytometry service of IRCCS National Cancer Institute, Milan. To evaluate apoptosis by annexin V
assay, cells were processed using the FITC Annexin V Apoptosis Detection Kit I (BD Pharmigen) and
TO-PRO-3 (1:2000, Thermo Fisher Scientific) following the manufacturer’s instructions. The samples
were processed on a FACSCanto (BD Biosciences), and the data were analyzed using FlowJo (TreeStar).
In each sample, the amount of viable cells in early apoptosis, late apoptosis, and necrosis was expressed
as the percentage of total cells. To evaluate the apoptotic cells fractions (expressed as percentage of total
number of cells evaluated) of each sample, we considered cells in early and late apoptosis phases, then
combining the percentage of cells positive for Annexin V, regardless of TO-PRO-3 staining. To calculate
the percentage of apoptotic cells’ ratio, the obtained percentage of total apoptotic cells treated with
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Poly(I:C)+IFNα were divided for the percentage of total apoptotic cells of the untreated samples, set as
reference. The same procedure was followed for the induction of apoptosis by Poly(A:U) 500 µg/mL in
lung cancer cell lines.
4.4. TUNEL Assay
The Calu-3 and H460 human lung cancer cell lines were seeded in 6-well plates and treated
with 100 U/mL INFα, as it is standard for determining the in vitro effects of TLR3 agonists [15].
After 24 h, the culture medium was replaced with 100 µg/mL Poly (I:C) (LMW) (tlrl-picw, InvivoGen)
and 100 U/mL INFα. After an additional 48 h, the supernatants from tumor cells, containing debris,
necrotic cells, and trypsin-detached cells, were centrifuged for 5 min at 1500 rpm. The recovered cells
were washed in 1X PBS. For the TUNEL assay, cytospins were settled: Recovered cells were placed on
Superfrost slides (Thermo Fisher Scientific) on a Thermo Shandon Cytospin 3 centrifuge and fixed with
paraformaldehyde 4%, pH 7.4. The cytospins were processed using the in situ Cell Death Detection
Kit-POD (Roche) following the manufacturer’s instructions.
4.5. Cytofluorometric Analysis of Caspase-3 Activation
Calu-3 cells were untreated or treated with a combination of 100 U/mL INFα and 100 µg/mL
Poly(I:C). After 48 h, the cells were stained with FITC Rabbit Anti-Active Caspase-3 (CPP32; Yama;
Apopain) (BD Pharmingen, cat. 5168654X) and propidium iodide (PI), and the percentage of cells
that were positive for caspase-3 was determined by FACS analysis. The samples were analyzed on a
FACSCanto (BD Biosciences), and the data were processed using FlowJo software (TreeStar).
4.6. Patients
Samples from 45 NSCLC patients who had been diagnosed between 2009 and 2011 at ASST
Grande Ospedale Metropolitano Niguarda were selected. The study was conducted in accordance
with the Declaration of Helsinki (World Medical Association, 2013), and the study was conducted after
the approval from the Niguarda Administrative Authority and the Independent Ethics Committee of
Milan Area 3 (Milan, Italy) (No. 253-062019).
4.7. Immunohistochemical Analysis of FFPE NSCLC Specimens
TLR3 and caspase-3 were analyzed by IHC on 2.5/3-µm formalin-fixed, paraffin-embedded (FFPE)
tumor sections, using the polyclonal anti-TLR3 clone 40F9.6 at 1:1000, which was developed by
Salaun et al. [32] and kindly provided by Innate Pharma (Innate Pharma, Marseille France), and the
monoclonal Cleaved Caspase-3 (Asp175) (5A1E) #9664 at 1:150. Briefly, for TLR3 staining, antigen
retrieval was performed by heating the slides for 10 min at 96 ◦C in EDTA 1mM pH 8; immunoreactions
were visualized using streptavidin-biotin-peroxidase (Thermo Fisher Scientific), 3,3′-diaminobenzidine
(DAB; brown signal) (Dako) as the chromogen. For caspase-3 staining, antigen retrieval was performed
by heating the slides for 10 min at 100 ◦C in citrate buffer pH 6 overnight; immunoreactions were
visualized using Novolink polymer system (Leica). The sections were counterstained with hematoxylin,
and immunoreactions were visualized and acquired as we already described [33,34]. The reactivity
of anti-TLR3 and of anti-caspase-3 in the IHC analysis of FFPE NSCLC specimens was scored as the
percentage of positive cells of the total number of cancer cells present in the tumor sample. TLR3
and caspase-3 expression was defined in tumor cells using a semiquantitative method that defined
the percentage of positive cells of the total number of cancer cells in the sample (0 = no positive cells;
1 ≤ 25%; 25% < 2 ≤ 50%; 50% < 3 ≤ 75%; 4 > 75%). Cases expressing TLR3 >50% of the total number of
cancer cells were compared with the remaining cases expressing TLR3 ≤50% of the total number of
cancer cells. The distribution of cases by expression pattern is shown in Figure S8.
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4.8. TLR3 Expression in NSCLC by Gene Expression Microarray
TLR3 expression was assessed in a large meta-analysis of NSCLC datasets on an Affymetrix
platform [19,35], as we already described for other cancer types [36]. Briefly, the online KM-Plotter
database, which includes information on 22,277 genes and their influence on survival in 1926 NSCLC
patients, was used for the survival analysis. NSCLC patients were stratified by tertiles of TLR3 mRNA
expression (probe ID 206271_at). The overall survival probability of patients by TLR3 mRNA expression
was calculated for adenocarcinoma NSCLC cases (n = 720), squamous NSCLC cases (n = 524), stage I
adenocarcinoma NSCLC cases (n = 370), and stage II adenocarcinoma NSCLC cases (n = 136).
4.9. Immunofluorescence Analysis of Mouse Lung Immune Infiltrates
Lung immune cells from the lungs of treated healthy mice were isolated as described [30].
Cell suspensions were stained directly for flow cytometry. Briefly, mouse lungs were homogenized
mechanically in DMEM medium that was supplemented with 10% fetal bovine serum (FBS), centrifuged
for 5 min at 1500 rpm and 4 ◦C, and digested in DMEM medium that contained 300 U/mL collagenase
and 100 U/mL hyaluronidase (Stemcell Technologies, 07912) for 1 h at 37 ◦C. Cell suspensions were
filtered through 40-µm cell strainers, and red blood cells were lysed in ACK (BioWhittaker LONZA)
for 10 min on ice. Next, the samples were centrifuged for 5 min at 1500 rpm at 4 ◦C and washed with
1× PBS.
Co-cultures were established in complete medium (RPMI 10% FBS, Na pyruvate 1:100, Hepes
1:100, glutamine 1:100, and penstrep 1:100, Thermo Fisher Scientific) by incubating 500,000 cancer cells
(Calu-3 or H460) that were pretreated with Poly (I:C) and INFα with 2,000,000 cells that had been
recovered from mouse lungs for 1.5 h or 4 h at 37 ◦C with gentle rocking. At the end of the incubation,
the cells were centrifuged for 5 min at 1500 rpm and washed in 1× PBS for FACS analysis.
Immunofluorescence staining was performed as already described [34]. Briefly, the cells were
labeled using the Live/Dead Fixable Violet Dead Cell Stain Kit (Life Technologies) for 30 min at 4 ◦C in
the dark, washed with 1× PBS, and stained for 30 min at 4 ◦C with the following directly conjugated
antibodies: anti-mouse CD11b Alexa Fluor 700, anti-mouse CD11c PE-Cy7, anti-mouse CD86 PE
(Milteny), hamster anti-mouse CD80 PE-CF594, rat anti-mouse CD83 BV510 (BD Horizon), anti-mouse
MHCII PERcP Vio700, and anti-mouse CD103 APC (Milteny). A purified rat anti-mouse CD16/CD32
MAb (eBiosciences, clone 93) was used to block nonspecific binding to mouse Fc receptors. Fluorescence
compensation was performed using CompBeads Anti-Rat, Anti-Hamster Ig, CompBeads Negative
Control (BD Biosciences), ArC reactive beads, and ArC negative beads (Life Technologies). The cells
were acquired with a Gallios flow cytometer (Beckman Coulter) and analyzed using FlowJo (TreeStar)
or Kaluza software (Beckman Coulter) with the gating strategy reported in Figure S6. Each experiments
has been performed at least two times, and a representative one is shown.
4.10. Statistical Analysis
In in vitro studies, data were expressed as mean ± standard deviation. Differences were tested
by two-tailed t-test; for two dependent groups, the equality of means was examined by two-tailed
paired t-test. Pearson’s correlation was used to analyze the association between TLR3 and caspase-3
expression in the Niguarda cohort. The values p < 0.05 were considered statistically significant. In the
INT cohort, OS was defined as the time between the date of surgery and the date of death from any
cause or the date of the last follow-up. Univariate survival analysis was carried out by phreg procedure
using a Cox regression model and the determination of the statistical significance of all categorical
predictors by chi-square test. The effects of explanatory variables on event hazard were quantified
by hazard ratios (HR), and 95% confidence limits (Cl) are indicated [37]. All statistical analyses were
conducted using SAS (SAS 9.4 Institute Inc., Cary, NC, USA).
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/21/4/1440/s1.
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